New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

amgen new zealand limited - darbepoetin alfa 15 µg/ml;   - solution for injection - 15 mcg/ml - active: darbepoetin alfa 15 µg/ml   excipient: dibasic sodium phosphate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

amgen new zealand limited - darbepoetin alfa 200 µg/ml;   - solution for injection - 200 mcg/ml - active: darbepoetin alfa 200 µg/ml   excipient: dibasic sodium phosphate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

amgen new zealand limited - darbepoetin alfa 25 µg/ml;   - solution for injection - 25 mcg/ml - active: darbepoetin alfa 25 µg/ml   excipient: dibasic sodium phosphate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

amgen new zealand limited - darbepoetin alfa 40 µg/ml;   - solution for injection - 40 mcg/ml - active: darbepoetin alfa 40 µg/ml   excipient: dibasic sodium phosphate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

amgen new zealand limited - darbepoetin alfa 500 µg/ml;   - solution for injection - 500 mcg/ml - active: darbepoetin alfa 500 µg/ml   excipient: dibasic sodium phosphate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

amgen new zealand limited - darbepoetin alfa 60 µg/ml;   - solution for injection - 60 mcg/ml - active: darbepoetin alfa 60 µg/ml   excipient: dibasic sodium phosphate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

amgen new zealand limited - pegfilgrastim 10 mg/ml;   - solution for injection - 6 mg/0.6ml - active: pegfilgrastim 10 mg/ml   excipient: acetic acid polysorbate 20 sodium hydroxide sorbitol water for injection - reduction in the duration of neutropenia, the incidence of febrile neutropenia and the incidence of infection as manifested by febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

amgen new zealand limited - filgrastim 600 µg/ml;   - solution for injection - 300 mcg/0.5ml - active: filgrastim 600 µg/ml   excipient: glacial acetic acid polysorbate 80 sodium hydroxide sorbitol water for injection - neupogen is indicated for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia and its clinical sequelae in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. the safety and efficacy of neupogen are similar in adults and children receiving cytotoxic chemotherapy. neupogen is indicated for the treatment of persistent neutropenia (anc less than or equal to 1.0 x 10^9/l) in patients with advanced hiv infection, in order to reduce the risk of bacterial infections, when other options to manage neutropenia are inappropriate.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

amgen new zealand limited - filgrastim 300 µg/ml;   - solution for injection - 300 mcg/ml - active: filgrastim 300 µg/ml   excipient: glacial acetic acid polysorbate 80 sodium hydroxide sorbitol water for injection - neupogen is indicated for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia and its clinical sequelae in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. the safety and efficacy of neupogen are similar in adults and children receiving cytotoxic chemotherapy. neupogen is indicated for the treatment of persistent neutropenia (anc less than or equal to 1.0 x 10^9/l) in patients with advanced hiv infection, in order to reduce the risk of bacterial infections, when other options to manage neutropenia are inappropriate.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

amgen new zealand limited - filgrastim 960 µg/ml (480 µg/syringe);   - solution for injection - 480 mcg/0.5ml - active: filgrastim 960 µg/ml (480 µg/syringe)   excipient: glacial acetic acid polysorbate 80 sodium hydroxide sorbitol water for injection - neupogen is indicated for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia and its clinical sequelae in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. the safety and efficacy of neupogen are similar in adults and children receiving cytotoxic chemotherapy. neupogen is indicated for the treatment of persistent neutropenia (anc less than or equal to 1.0 x 10^9/l) in patients with advanced hiv infection, in order to reduce the risk of bacterial infections, when other options to manage neutropenia are inappropriate.